Related Experiment Video
Updated: Feb 27, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Dramatic response of metaplastic breast cancer to chemo-immunotherapy
1New York University School of Medicine, Perlmutter Cancer Center, New York, NY USA.
Abstract:
Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment

